The acquisition will strengthen GSK’s immunology pipeline, which is a key area of focus for the pharma company.

With star checkpoint inhibitors like Keytruda and Opdivo now sporting subcutaneous formulations, GSK has struck a deal aimed ...

Alteogen Inc. (KOSDAQ: 196170) announced today that the company has entered into an exclusive license agreement with Tesaro, Inc., a subsidiary of GSK. Under the terms of the agreement, Tesaro will ...

GSK noted recent deals as source of fresh revenues amid patent expiries and an AI-driven boost to drug discovery.

Now in its second year, the GSK Community Health programme, delivered in partnership with The King's Fund, provides funding and development support to 10 very small charities tackling health ...

Chai Discovery, Noetik, and Boltz have entered multi-year pharma partnerships focused on models, not molecules, hinting at AI’s “infrastructure moment.” ...

South Korean biotech Alteogen (Kosdaq: 196170) has signed an exclusive license agreement with Tesaro, a unit of GSK (LSE: GSK ...

Alteogen has signed a licensing agreement with Tesaro, a subsidiary of global pharmaceutical powerhouse GSK, for the ...

Alteogen inks licensing agreement with Tesaro to develop subcutaneous formulation of dostarlimab enabled by Hybrozyme Technology: Daejeon, South Korea Wednesday, January 21, 2026, ...

GSK, Pfizer and Shionogi agree on changes to ViiV Healthcare shareholding: London, UK Wednesday, January 21, 2026, 09:00 Hrs [IST] GSK plc (GSK), and Shionogi & Co., Ltd (Shionogi ...